Floatz logo

Zalifrelimab

Advanced Solid Cancers

Agenus Inc.monoclonal_antibodyPhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Advanced Solid Cancers cohort.

Asset / SponsorPhaseRating
FENTANYL
Gachon University Gil Medical Center
Phase 2B
prl3-zumab
Intra-IMMUSG Pte Ltd
Phase 2/3B
Oxycodone
Gachon University Gil Medical Center
Phase 2B
BMS-863233
Bristol-Myers Squibb
Phase 1/2CC
Memory-Like Nk Cells
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2CC

View all 22 →

Same molecule, other indications

Zalifrelimab is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
refractory malignant neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →
head and neck squamous cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →